Insider Buying: vTv Therapeutics Inc (NASDAQ:VTVT) Major Shareholder Acquires 606,061 Shares of Stock

Share on StockTwits

vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman acquired 606,061 shares of vTv Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $1,000,000.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

vTv Therapeutics stock traded up $0.06 during trading hours on Friday, hitting $1.49. The stock had a trading volume of 166,639 shares, compared to its average volume of 481,015. vTv Therapeutics Inc has a one year low of $1.00 and a one year high of $4.59. The business’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.46.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million. As a group, analysts predict that vTv Therapeutics Inc will post -0.53 earnings per share for the current fiscal year.

An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. lifted its stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,031 shares of the biotechnology company’s stock after acquiring an additional 13,305 shares during the quarter. BlackRock Inc. owned approximately 0.12% of vTv Therapeutics worth $93,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.64% of the company’s stock.

VTVT has been the topic of several research analyst reports. Northland Securities set a $8.00 price objective on vTv Therapeutics and gave the company a “buy” rating in a research note on Wednesday. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of vTv Therapeutics in a research report on Friday, August 16th.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Further Reading: Rule of 72

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.